Argenica Therapeutics (AU:AGN) — Company Overview, News & Financial Data
Argenica Therapeutics is a biopharmaceutical company pioneering neuroprotective therapeutics for stroke recovery.
About Argenica Therapeutics
Argenica Therapeutics (ASX:AGN) is a clinical-stage biopharmaceutical company pioneering neuroprotective therapeutics to mitigate brain damage after stroke and other ischemic brain injuries. Their lead candidate, ARG-007, is a synthetic peptide designed to target and modulate key cellular pathways triggered by oxygen deprivation, thereby preserving neuronal viability and limiting tissue loss. ARG-007 has demonstrated potential in preclinical models to reduce infarct size, improve neurological function, and enhance post-stroke recovery. Currently in Phase 2 clinical trials, Argenica aims to translate this therapeutic promise into improved outcomes for stroke patients, a critical unmet medical need affecting millions worldwide.
Snapshot
Operations
Products and/or services of Argenica Therapeutics
- Tackling Stroke: developing novel neuroprotective therapies to minimise brain damage after stroke, a leading cause of disability and mortality globally.
- Promising Lead Candidate: ARG-007, a synthetic peptide, targets key cellular pathways triggered by oxygen deprivation, aiming to preserve neurons and limit tissue loss.
- Preclinical Success: ARG-007 demonstrated efficacy in preclinical models, reducing infarct size, improving neurological function, and enhancing post-stroke recovery.
- Phase 2 Clinical Trials: currently investigating ARG-007's safety and efficacy in human patients with acute ischemic stroke, a crucial step towards market approval.
- Beyond Stroke: exploring the potential of ARG-007 to treat other ischemic brain injuries, such as traumatic brain injury and hypoxic-ischemic encephalopathy in newborns.
- Committed to Innovation: actively researching and developing next-generation neuroprotective therapies to further improve patient outcomes and revolutionize stroke treatment.
Argenica Therapeutics executive team
- Dr. Liz Dallimore B.Sc., M.B.A., Ph.D.CEO, MD & Director
- Ms. Emma WaldonCFO & Company Secretary
- Prof. Bruno Philip MeloniChief Scientific Officer